PineBridge Investments L.P. boosted its stake in shares of MiMedx Group Inc. (NASDAQ:MDXG) by 8.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,643 shares of the company’s stock after buying an additional 992 shares during the period. PineBridge Investments L.P.’s holdings in MiMedx Group were worth $101,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in MDXG. Springbok Capital Management LLC bought a new stake in MiMedx Group during the first quarter valued at approximately $109,000. Mckinley Capital Management LLC Delaware bought a new stake in MiMedx Group during the first quarter valued at approximately $112,000. Teacher Retirement System of Texas increased its stake in MiMedx Group by 26.3% in the second quarter. Teacher Retirement System of Texas now owns 14,361 shares of the company’s stock valued at $115,000 after buying an additional 2,994 shares during the last quarter. Commonwealth Equity Services Inc increased its stake in MiMedx Group by 15.8% in the second quarter. Commonwealth Equity Services Inc now owns 14,623 shares of the company’s stock valued at $117,000 after buying an additional 2,000 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in MiMedx Group by 9.0% in the first quarter. Legal & General Group Plc now owns 16,183 shares of the company’s stock valued at $142,000 after buying an additional 1,343 shares during the last quarter. Institutional investors own 44.35% of the company’s stock.
MiMedx Group Inc. (NASDAQ:MDXG) opened at 8.86 on Friday. MiMedx Group Inc. has a 12-month low of $6.64 and a 12-month high of $10.00. The stock has a market cap of $974.97 million, a PE ratio of 41.99 and a beta of 0.70. The firm has a 50-day moving average of $8.20 and a 200-day moving average of $7.91.
MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.05 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by $0.02. The firm had revenue of $57 million for the quarter, compared to analysts’ expectations of $56.49 million. MiMedx Group had a return on equity of 22.16% and a net margin of 10.92%. The firm’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS. Equities analysts predict that MiMedx Group Inc. will post $0.22 earnings per share for the current fiscal year.
Several research firms have recently commented on MDXG. Zacks Investment Research upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Wednesday, June 29th. Brean Capital reiterated a “buy” rating on shares of MiMedx Group in a research note on Wednesday, June 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $12.00 price objective on shares of MiMedx Group in a research note on Wednesday, August 31st. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.89.
In other MiMedx Group news, insider William Charles Taylor sold 20,400 shares of the company’s stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $7.55, for a total transaction of $154,020.00. Following the completion of the transaction, the insider now owns 566,566 shares in the company, valued at approximately $4,277,573.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 12.30% of the company’s stock.
MiMedx Group Company Profile
MiMedx Group, Inc (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories.
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group Inc. (NASDAQ:MDXG).
Receive News & Ratings for MiMedx Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.